Sante Ventures

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 79
Average round size
info
The average size of a deal this fund participated in
$9M
Portfolio companies 39
Rounds per year 4.94
Lead investments 23
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.51
Exits 12
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Therapeutics
  • Medical Device
Summary

Sante Ventures is the famous VC, which was founded in 2007. The venture was found in North America in United States. The main office of represented VC is situated in the Austin.

The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Sante Ventures, startups are often financed by Prolog Ventures, ONSET Ventures, Highland Capital Partners. The meaningful sponsors for the fund in investment in the same round are Austin Ventures, MB Venture Partners, Prolog Ventures. In the next rounds fund is usually obtained by Square 1 Bank, Prolog Ventures, Austin Ventures.

The top activity for fund was in 2013. Despite it in 2019 the fund had an activity. Comparing to the other companies, this Sante Ventures performs on 7 percentage points less the average number of lead investments. The top amount of exits for fund were in 2018. The real fund results show that this VC is 57 percentage points more often commits exit comparing to other companies. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is generally included in 2-6 deals every year.

Besides, a startup needs to be aged 6-10 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Therapeutics, Biotechnology. Among the most popular portfolio startups of the fund, we may highlight Lumos Pharma, Zeno Corporation, EndoStim. The fund has exact preference in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

The overall number of key employees were 4.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Sante Ventures:
Typical Co-investors
Sante Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Sante Ventures:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Allen Institute for Artificial Intelligence Seattle, United States, Washington
AO Capital Partners China, Hong Kong, Hong Kong Island
ARTKB -
Club Acceleratori Italy, Lombardia, Milano
Creative England Bristol, England, United Kingdom
East Coast Angels New Hampshire, Portsmouth, United States
FOREVER 21 -
Furui Jiacheng Investment Management China, Songjiang, Songjiang District
GREE VR Capital California, San Francisco, United States
Groupe Rossel Belgium, Brussels, Brussels Hoofdstedelijk Gewest
Jubilant Biosys Bengaluru, India, Karnataka
Labora Group Dallas, Texas, United States
One Planet California, United States, Walnut Creek
Quire New York, New York, United States
Quotas Beteiligungs Germany, Hoisdorf, Schleswig-Holstein
Radical Investments LP Dallas, Texas, United States
Taiyuan Kechuang Jiade Chuangye Touzi Zhongxin China, Shanxi, Taiyuan
Tudor Growth Equity Boston, Massachusetts, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Endovascular Engineering

Clinical Trials
Medical
Medical Device
$15M05 Apr 2022 Menlo Park, California, United States

Geneos Therapeutics

Biotechnology
Health Care
Pharmaceutical
Therapeutics
$17M24 Mar 2022 Whitemarsh Township, Pennsylvania, United States

Reimagine Care

Health Care
Hospital
Medical
$25M25 Jan 2022 Nashville, Tennessee, United States

Access Optics

Commercial
Machinery Manufacturing
Manufacturing
Medical
Service Industry
$4M25 Oct 2021 Broken Arrow, Oklahoma, United States

Cryosa

Biotechnology
Clinical Trials
Health Care
Medical Device
$21M23 Sep 2021 Minnesota, United States

RapidPulse

Health Care
Medical Device
$15M23 Jun 2021 Miami, Florida, United States

Geneos Therapeutics

Biotechnology
Health Care
Pharmaceutical
Therapeutics
$12M03 Mar 2021 Whitemarsh Township, Pennsylvania, United States

Iterion Therapeutics

Biotechnology
Pharmaceutical
Therapeutics
$17M16 Feb 2021 Houston, Texas, United States

Nirogy Therapeutics

Biopharma
Biotechnology
Pharmaceutical
$16M26 Jan 2021 Massachusetts, United States
News
RapidPulse Raises $15M in Series A Funding

– RapidPulse from Miami FL raised $15M in Series A funding.
– The round was led by Santé Ventures with participation from Epidarex Capital, Hatteras Venture Partners, Broadview Ventures, and Syntheon.
– The company plans to use the funds to advance its system through expanded clinical evaluation and build out its platform of proprietary catheters.

Geneos Therapeutics Raises $12M in Series A1 Financing

– Geneos Therapeutics from Plymouth Meeting, Pa. develops personalized neoantigen-targeting immunotherapies for cancer.
– The company raised $12m in Series A1 funding.
– The round was led by Korea Investment Partners (KIP) – Global Bio Fund with participation from existing investors Santé Ventures and Inovio Pharmaceuticals, Inc. (NASDAQ: INO).
– The company plans to use the funds for the expansion of the company’s:
– GT-30 Phase Ib/IIa clinical trial evaluating its personalized neoantigen-targeting vaccine,

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Sante Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: